MEDICAMEN Organics Limited

Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)
Tel: 011-27430249, 27138171
E-mail: info@mediorganics.in | **CIN No:** L74899DL1995PLC066416 | **GSTIN:**07AABCM4302P1ZF

November 14, 2025

To,
National Stock Exchange of India Limited
Listing & Compliance Department
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex, Bandra
Mumbai - 400051, India

Company Symbol : **MEDIORG**
Company ISIN : **INE0PE401018**

Subject: Outcome of Board Meeting pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations'), we are pleased to inform you Board of Directors of Medicamen Organics Limited at their meeting held on Friday, 14th November, 2025 at the Registered office of the Company situated at -10, Community Centre No.2, Ashok Vihar Phase-II, Delhi -110052 India inter-alia, considered the following matters:-

1. Considered, approved and took on record the Standalone and Consolidated Un-Audited Financial Results, duly reviewed by the Audit Committee, along with Limited Review Report submitted by the Statutory Auditor of the Company for the half year ended on September 30, 2025.

In compliance with Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2024 the Unaudited Standalone and Consolidated Financial Results along with the Limited Review Report is annexed along with this letter as **Annexure I**.

Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find herewith attached Certificate issued by the Statutory Auditors in respect of utilization of issue proceeds in terms of NSE Circular No. NSE/CML/2024/23 dated September 05, 2024 **Annexure II**.

2. Appointment of M/s. Gupta Shobhit & Associates, Chartered Accountant Firm as the Internal Auditors of the Company as recommended by Audit Committee, for the Financial Year 2025-26 in terms of Section 138 of the Companies Act, 2013 for undertaking the Internal Audit of the Company.

The details as required in compliance with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 are annexed as **Annexure III**.

The Board meeting commenced at 04:00 PM and concluded at 06:25 PM

This is for your information and records.

Thanking You,

For Medicamen Organics Limited

Bal Kishan Gupta
Digitally signed by Bal Kishan Gupta
Date: 2025.11.14 18:27:56 +05'30'

Bal Kishan Gupta
Managing Director
DIN: 00032772

Place: New Delhi

N C RAJ & ASSOCIATES
Chartered Accountants
10, Community Centre No.2,
Ashok Vihar Phase-II,
Delhi – 110 052
Phone: +919810831648
+919810262603
Website: www.ncraj.com
Email: info@ncraj.com
Peer Review No.: 014034

Annexure I

Auditor's Limited Review Report on unaudited Standalone Financial results of Medicamen organics Limited, for the Half year ended September 30, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors of,
Medicamen Organics Limited

We have reviewed the accompanying statement of unaudited Standalone financial results of **Medicamen organics Limited** for the half year ended September 30, 2025 being submitted by the company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circular issued by the SEBI from time from time.

The statement, which is the responsibility Of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25, lnterim Financial Reporting' ('AS 25`), prescribed under section 133 of the Companies Act. 2013 (the Act'), SEBI Circular CIR/CFD/FAC/62/2016 dated 5th July, 2016, (herein after referred to as the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the independent Auditor of the Entity", issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primary to inquire of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone financial results prepared in accordance with the recognition and measurement principles laid down in AS 25, prescribed under


Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

EMPHASIS OF MATTER

- In reference to **Note no. 10** of the statement which explains that, the figures for the half-year ended March 31st, 2025 are balancing figures between audited figures in respect of the full financial year ended March 31st, 2025 and the unaudited half-year ended September 30th 2024.
- The company has not made Provision for the Case filed by Prakash Parcel Services Ltd. Against the company as referred in **Note No 11a** of unaudited financial results, as the matters are pending before Rohini Court. We are unable to comment upon possible impact of non-provision in the standalone financial statement for the half year ended 30th September 2025.
- The company has not made Provision for the demand raised by various authorities (Such as Income Tax, GST etc.) as referred in **Note No 11b** of unaudited financial results, as the matters are pending before various appellate forums. We are unable to comment upon possible impact of non-provision in the standalone financial statement for the half year ended 30th September 2025.
- In reference to **Note no. 11c** of the statement which explains the details of pending litigation (total 6 civil recovery suit) and all matters are pending before Rohini (Court Delhi).
- In reference to **Note no. 12** of the statement which explains statement of deviation/ variation in utilisation of funds raised thru IPO and auditor comments on such statement that there is no deviation in utilisation of funds.
- In reference to **Note no. 13** of the statement which explains statement of deviation/ variation in utilisation of funds raised thru Share Warrant and auditor comments on such statement that there is no deviation in utilisation of funds
- In reference to **Note No.14**, balances of some debtors and creditors are subject to their confirmations.
- In reference to **Note no. 15** of the statement which explains as per the assessment of the management, the recoverable amount of assets is higher than it carrying value and hence no impairment of assets needs to be recorded in the financial statements.

Our conclusion is not modified in respect of this matter.

For N C RAJ & ASSOCIATES
Chartered Accountants
(FRN: 002249N)



SANJAY GARG
Partner
Mem. No. 088636
Date: November 14th 2025
Place: New Delhi
UDIN: 25088636BMMJGX1060

MEDICAMEN ORGANICS LIMITED

Registered Address: 10, Community Centre No 2,
Ashok Vihar Phase II New Delhi - 110052
CIN : L74899DL1995PLC066416

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS AS AT SEPTEMBER 30TH, 2025

(Rs. in Lakhs)

	PARTICULARS	Figures as at the end of	
		As At 30.09.2025	As At 31.03.2025
		Unaudited	Audited
I.	**EQUITY AND LIABILITIES**		
1	**Shareholders' funds**		
	(a) Share Capital	1170.00	1170.00
	(b) Reserves and Surplus	1921.30	1727.49
	(c) Money received against Share Warrants	125.00	75.00
		3216.30	**2972.49**
2	**Share Application Money Pending Allotement**		
3	**Non- current liabilities**		
	(a) Long-term borrowings	36.68	15.75
	(b) Deferred Tax liabilities	118.01	115.99
	(c) Long-term Provisions	26.96	25.34
		181.65	**157.08**
4	**Current Liabilities**		
	(a) Short term borrowings	1438.82	1197.20
	(b) Trade payables		
	- Outstanding dues of Micro and Small Enterprises	101.59	108.75
	- Outstanding dues to others	614.44	1058.05
	(c) Other current liabilities	145.87	128.30
	(d) Short term provisions	189.66	122.60
		2490.37	**2614.89**
	TOTAL	**5888.32**	**5744.46**
II	**ASSETS**		
1.	**Non-current assets**		
	(a) Property, Plant & Equipment		
	(i) Property, Plant & Equipment	1266.68	1011.54
	(ii) Intangible assets	11.31	1.43
	(iii) Capital work-in-progress	35.93	221.59
	(b) Non-Current Investment	27.00	27.00
	(b) Long-term Loans & Advances	25.13	-
	(c) Other Non-Current Assets	134.46	141.18
		1500.51	**1402.74**
2.	**Current assets**		
	(a) Inventories	820.01	748.94
	(b) Trade receivables	2620.91	2475.22
	(c) Cash and cash equivalents	231.09	326.91
	(d) Short-term loans and advances	715.81	790.66
	(e) Other current assets	-	-
		4387.81	**4341.72**
	TOTAL	**5888.32**	**5744.46**

For MEDICAMEN ORGANICS LTD.

Director

B.K. Gupta
(Chairman cum Managing Director)
DIN:00032772

Place : New Delhi
Date: 14th November 2025

MEDICAMEN ORGANICS LIMITED

Registered Address: 10, Community Centre No 2,
Ashok Vihar Phase II New Delhi - 110052
CIN : L74899DL1995PLC066416

STATEMENT OF UNAUDITED STANDALONE PROFIT AND LOSS FOR THE HALF YEAR ENDED 30.09.2025

(Rs. in Lakhs)

	PARTICULARS	For the Half Year ended			For the year ended March 31, 2025
		From 01-04-2025 to 30-09-2025	From 01-10-2024 to 31-03-2025	From 01-04-2024 to 30-09-2024	
		Unaudited	Audited	Unaudited	Audited
I	Revenue from operations:	1705.16	2047.72	1661.04	3708.77
II	Other Income	5.74	5.21	4.29	9.50
III	**Total Revenue (I + II)**	**1710.90**	**2052.94**	**1665.34**	**3718.27**
IV	**Expenses**				
	Cost of Materials Consumed	1020.41	1248.88	975.67	2224.54
	Direct Expenses	155.48	179.43	153.18	332.61
	Changes in inventories of finished goods, work in progress and Stock-in- trade	-112.90	-95.19	14.40	-80.79
	Employee benefits expense	185.48	191.28	174.62	365.91
	Finance Costs	33.32	29.10	22.17	51.27
	Depreciation and amortization expense	41.19	37.28	36.41	73.68
	Other expense	129.17	242.32	70.03	312.36
	Total Expense	**1452.17**	**1833.10**	**1446.48**	**3279.58**
V	**Profit before exceptional and extraordinary items and tax (III-IV)**	258.74	219.84	218.85	438.69
VI	**Exceptional Items**	-	-	-	-
VII.	**Profit before extraordinary items and tax (V-VI)**	258.74	219.84	218.85	438.69
VIII	**Prior Period Item/Extraordinary items(Loss**	-	-	-	0.00
IX	**Profit before tax (VII-VIII)**	**258.74**	**219.84**	**218.85**	**438.69**
X	**Tax expense:**				
	(1) Current tax	62.90	52.73	61.43	114.17
	(2) Deferred tax	2.02	-8.90	6.35	-2.55
XI	**Profit/(Loss) for the period from continuing operations (IX - X)**	193.82	176.00	151.07	327.08
XII	**Profit/(Loss) for the period**	**193.82**	**176.00**	**151.07**	**327.08**
XV	**Earnings per equity share:**				
	(1) Basic	**1.66**	**1.50**	**1.48**	**2.98**
	(2) Diluted	**1.63**	**1.50**	**1.48**	**2.98**

For MEDICAMEN ORGANICS LTD.

Director

B.K. Gupta
(Chairman cum Managing Director)
DIN:00032772

Place : New Delhi
Date: 14th November 2025

MEDICAMEN ORGANICS LIMITED

Registered Address: 10, Community Centre No 2,
Ashok Vihar Phase II New Delhi - 110052
CIN : L74899DL1995PLC066416

UNAUDITED STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2025

(Rs. in Lakhs)

Particulars	Figures as at the end of	
	As At 30.09.2025	As At 31.03.2025
	Unaudited	Audited
	-	
Cash flow from operating activities		
Net profit before taxation, and extraordinary item	258.73	438.69
Non-cash adjustment to reconcile profit before tax to net cash flows		
Provision for Taxation	-	-
Depreciation/amortization on continuing operation	14.60	59.73
Interest expense	33.32	51.27
Interest income	-1.56	-9.48
Adjustment for Deffered Tax	-	-
Operating profit before working capital changes	**305.09**	**540.21**
Movements in working capital :		
Increase/(decrease) in trade payables	-450.77	458.83
Increase / (decrease) in long-term provisions	1.62	3.87
Increase / (decrease) in short-term provisions	4.17	-90.08
Increase/(decrease) in other current liabilities	17.57	22.37
Decrease/ (increase) in long term loans and advances	-25.13	32.50
Decrease/ (increase) in trade receivables	-145.69	-805.21
Decrease/ (increase) in inventories	-71.07	-134.67
Decrease / (increase) in other non-current Assets	6.72	-110.46
Decrease / (increase) in short-term loans and advances	74.84	-399.00
Decrease/(increase) in other current assets	-	-
Direct taxes paid (net of refunds)	0.00	-9.44
Net cash flow from/ (used in) operating activities (A)	**-282.65**	**-491.08**
Cash flows from investing activities		
Purchase of fixed assets, including intangible assets and CWIP	-93.96	-244.82
Investing to make Subsidiary and Associate concern	-	-27.00
Interest received	1.56	9.48
Net cash flow from/(used in) investing activities (B)	**-92.40**	**-262.34**
Cash flows from financing activities		
Proceeds from issuance of share capital	-	310.00
Share Warrants A/c	50.00	75.00
Proceeds from Securities Premium	-	744.00
Repayment of long-term borrowings	20.93	-0.39
Proceeds from short-term borrowings	241.62	-52.31
Interest paid	-33.32	-51.27
Net cash flow from/(used in) in financing activities (C)	**279.22**	**1025.03**
Net increase/(decrease) in cash and cash equivalents (A + B + C)	**-95.82**	**271.61**
Cash and cash equivalents at the beginning of the year (D)	326.91	55.30
Cash and cash equivalents at the end of the year (E)	231.09	326.91
Difference in above D and E	**-95.82**	**271.61**

For MEDICAMEN ORGANICS LTD.

B.K. Gupta
(Chairman cum Managing Director) Director
DIN:00032772

Place : New Delhi
Date: 14th November 2025

MEDICAMEN ORGANICS LIMITED

Registered Address: 10, Community Centre No 2,
Ashok Vihar Phase II New Delhi - 110052, India
CIN : L74899DL1995PLC066416

Notes to Accounts

1 The standalone financial results are prepared in accordance with the Accounting Standards Prescribed urder Section 133 of the Companies Act,2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable.

2 The Statutory Auditors of the Company have reviewed of the above results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

3 There were no investor complaints known to the Company outstanding at the beginning and at the end of the half year ended on September 30th, 2025.

4 The results of the Company are also available for investors at www.medicamenorganics.com and www.nseindia.com

5 The above standalone audited financial results for the Half year ended September 30th, 2025 have been prepared by the Company were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on November 14th, 2025, Above results has been reviewed by the statutory auditors of the company.

6 These financial results have been prepared in accordance with the recognition and measurement principles of Accounting Standards ("AS") prescribed section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and the other accounting principles generally accepted in India.

7 The company has received intimation from suppliers regarding their status under Micro, Small and Medium Enterprises Development Act 2006 and disclosures relating to the amount unpaid as at year end, as required under the said Act, have been provided. The Company has provided the interest on outstanding from supplier under Micro, Small and Medium Enterprises as on 30-09-2025.

8 The Earning Per Share (EPS) has been computed in accordance with the Accounting Standard on Earnings Per Share (AS 20). EPS for the half year ended September 30th, 2025, March 31st, 2025, and September 30th 2024 are not annuualised. The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earnings per share in accordance with the Accounting Standard 20.

9 The comparative results for the half-year ended September 30th, 2025 have been reviewed by the statutory auditors of the Company.

10 The figures for the half-year ended March 31st, 2025 are balancing figures between audited figures in respect of the full financial year ended March 31st, 2025 and the unaudited half-year ended September 30th 2024.

11 **CONTINGENT LIABILITIES AND PENDING LITIGATIONS**

a) **Contingent Liabilities** (In Lakhs)

Particulars	Next date of Hearing	As at 30-09-2025	As at 31-03-2025
a. Case against the company filed by Prakash Parcel Services Ltd.	10-12-2025	2.34	2.34
b. Margin money (FDR) for Bank Guarantee on behalf of third party		6.42	6.42

For MEDICAMEN ORGANICS LTD.

Director

b)

Name of the statute	Nature of the dues	Amount (Rs. in lakhs)	Financial Year	Description	Forum where dispute is pending
Income Tax Department	Income tax	13.27	AY 2017-18	Assessment year	Commissioner of income tax (Appeal)
GST	Difference in output tax liability & ITC claimed	5.87	2020-21	Reply is to be filed	Deputy Commissioner (Assessment)-2 Haridwar
GST	Difference in output tax liability & ITC claimed	89.73	2018-19	Appeal filed	Appeal filed before the Joint Commissioner (Appeals) Dehra Dun
GST	Difference in output tax liability & ITC claimed	74.51	2019-20	Appeal filed	Appeal to be filed before the Joint Comm. (Appeals) Dehra Dun
GST	Difference in output tax liability & ITC claimed	17.74	2022-23	Reply is to be filed	Deputy Commissioner (Assessment)-2 Haridwar

c) **Detail of Pending Litigation**

Name of the Party	Nature of the dues	Amount (Rs. in lakhs)	Next date of Hearing	Description	Forum where dispute is pending
Europa Biocare P Ltd	Civil Case	7.23	12-11-2025	The company has filed recovery suit (civil case) against the defaulter party	Rohini (Court)
M/S Wafture Healthcare P Ltd	Civil Case	5.7	24-12-2025	The company has filed recovery suit (civil case) against the defaulter party	Rohini (Court)
Paseca Health Care	Civil Case	5.53	05-12-2025	The company has filed recovery suit (civil case) against the defaulter party	Rohini (Court)
Ujjwal Overseas	Civil Case	17.17	05-12-2025	The company has filed recovery suit (civil case) against the defaulter party	Rohini (Court)
Mexlife Care LLP	Civil Case	18.22	23-02-2026	The company has filed recovery suit (civil case) against the defaulter party	Rohini (Court)
The Managing Director KSMSCL(Karnataka State)	Civil Case	148.22	12-11-2025	The company has filed recovery suit (civil case) against the defaulter party	Rohini (Court)

For MEDICAMEN ORGANICS LTD.

Director

Annexure A

12 During the period ended September 30th, 2025, the Company came up with the public issue of 31,00,000 equity shares of Face value of ₹ 10/- each ("equity shares") with the price band of ₹ 32 to 34 through Book Building Method, IPO was open for subscription from Friday, June 21, 2024 to Tuesday, June 25, 2024. The Company has allotted 31,00,000 equity shares of Face value of 10/- each ("equity shares") for cash at a price of ₹ 34/- per equity share (including a share premium of ₹ 24/- per equity share) aggregating to ₹ 1054.00 Lakhs on Wednesday, June 26, 2024. The equity shares of the Company got listed with Emerge platform of National Stock Exchange of India Limited on June 28, 2024. The issue was made in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.

Rs. In Lakhs

Object of the Issue as per Prospectus	Utilisation Planned as per prospectus	Total Utilisation up to September 30th, 2025	Amount Pending for Utilisation
Funding of expenses proposed to be incurred towards Product registration in the international markets	300	137.56	162.44
Plant updation and increase in production capacity	225	225	-
Funding working capital requirements of our Company	400	400	-
General corporate purposes	39	39	-
Issue Related Expenses	90	90	-
TOTAL	**1054**	**891.55815**	**162.44**

Note on Capitalisation of Product Registration Expenses (Object of the Issue)

As stated in the **Objects of the Issue** in the Company's Prospectus, one of the purposes of the public issue is to incur expenditure towards **Product Registration and Intellectual Property (IP) Development**.

Accordingly, the Company has incurred various expenses towards the registration and development of new products, and as per Prospectus of the company, Registration involves the preparation and submission of data dossiers which require detailed product specifications, understanding of the market dynamics and accurate compilation of required documents. Detailed study on the effect and the efficacy of the product is required to be conducted and details of the results of these studies are submitted as part of the registration process.

Expenditure directly attributable to such activities has been treated as part of **"Intellectual Property (IP) Work-in-Progress"**, in accordance with the recognition criteria laid down in **AS 26– Intangible Assets**.

The following costs have been capitalised under *IP Work-in-Progress* :

Regulatory and product registration fees;

Registration involves the preparation and submission of data dossiers which require detailed product specifications, understanding of the market dynamics and accurate compilation of required documents. Detailed study on the effect and the efficacy of the product is required to be conducted and details of the results of these studies are submitted as part of the registration process.

Upon completion of the registration process and readiness for commercial production, the cumulative expenditure will be **transferred from "IP Work-in-Progress" to "Intangible Assets – Product Registration / Intellectual Property"**, and **amortised over its estimated useful life**.

* The unutilsed proceeds are in company's account.

For MEDICAMEN ORGANICS LTD.

Director

13 During the financial year ended March 31, 2025, the Company came up with the preferential issue of 4,65,910 warrants convertible into equivalent number of fully paid-up equity shares of face value of ₹ 10/- (Rupee Ten Only) each ("Equity Shares") at the option of Allottees, in one or more tranches, within 18 (eighteen) months from the date of allotment at issue price of ₹ 64.39/-.
The issue was made in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.

In Lakhs

Object as disclosed in the offer document	Nature	Amount disclose in the Offer Document/ Postal Ballot Notice dated January 08, 2025 (Rs. In Lakhs)	Actual Utilised Amount (as on September 30, 2025)	Unutilised Amount (As on September 30, 2025)	Remarks, If any
(a) working capital requirements;	4,65,910 Share Warrants convertible into Equity Shares	299.99	123.25	-	As on September 30th, 2025, funds received against the warrants subscription money on 4,65,910 warrants amounted to ₹2,99,99,945, constituting 41.67% of the total funds raised. Out of the received funds, the Company has spent ₹1,25,00,000 towards the objects disclosed in the offer document/Postal Ballot Notice.
(b) general corporate purpose.			1.75	-	
Total	**Total**	**299.99**	**125.00**	-	

14 Balances of some debtors and creditors are subject to their confirmations.

15 As per the assessment of the management, the recoverable amount of assets is higher than it carrying value and hence no impairment of assets needs to be recorded in the financial statements.

16 Previous year/period's figures have been regrouped/reclassified wherever necessary to correspond with the current period's classification for comparison.

17 As the Company's business activity falls within a single primary business segment i.e. the disclosure requirements as per AS 17 "Segment Reporting" are not applicable.

For & on behalf of Medicamen Organics Limited

For MEDICAMEN ORGANICS LTD.

Director

Bal Kishan Gupta
(Chairman cum Managing Director)
DIN:00032772

Place : New Delhi
Date: 14th November 2025

N C RAJ & ASSOCIATES
Chartered Accountants
10, Community Centre No.2,
Ashok Vihar Phase-II,
Delhi – 110 052
Phone: +919810831648
+919810262603
Website: www.ncraj.com
Email: info@ncraj.com
Peer Review No.: 014034

Auditor's Limited Review Report on unaudited Consolidated Financial results of Medicamen organics Limited, for the Half year ended September 30, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors of,
Medicamen Organics Limited

We have reviewed the accompanying statement of unaudited consolidated financial results of **Medicamen organics Limited** for the half year ended September 30, 2025 being submitted by the company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circular issued by the SEBI from time from time.


The statement, which is the responsibility Of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25, lnterim Financial Reporting' ('AS 25`), prescribed under section 133 of the Companies Act. 2013 (the Act'), SEBI Circular CIR/CFD/FAC/62/2016 dated 5th July, 2016, (herein after referred to as the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the independent Auditor of the Entity", issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primary to inquire of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with the recognition and measurement principles laid down in AS 25, prescribed under section 133 Of the Act the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

EMPHASIS OF MATTER

- In reference to **Note no. 10** of the statement which explains that, the figures for the half-year




ended March 31st, 2025 are balancing figures between audited figures in respect of the full financial year ended March 31st, 2025 and the unaudited half-year ended September 30th 2024.

- The company has not made Provision for the Case filed by Prakash Parcel Services Ltd. Against the company as referred in **Note No 11a** of unaudited financial results, as the matters are pending before Rohini Court. We are unable to comment upon possible impact of non-provision in the standalone financial statement for the half year ended 30th September 2025.
- The company has not made Provision for the demand raised by various authorities (Such as Income Tax, GST etc.) as referred in **Note No 11b** of unaudited financial results, as the matters are pending before various appellate forums. We are unable to comment upon possible impact of non-provision in the consolidated financial statement for the half year ended 30th September 2025.
- In reference to **Note no. 11c** of the statement which explains the details of pending litigation (total 6 civil recovery suit) and all matters are pending before Rohini (Court Delhi).
- In reference to **Note no. 12** of the statement which explains statement of deviation/ variation in utilisation of funds raised thru IPO and auditor comments on such statement that there is no deviation in utilisation of funds.
- In reference to **Note no. 13** of the statement which explains statement of deviation/ variation in utilisation of funds raised thru Share Warrant and auditor comments on such statement that there is no deviation in utilisation of funds
- In reference to **Note No.14**, balances of some debtors and creditors are subject to their confirmations.
- In reference to **Note no. 15** of the statement which explains as per the assessment of the management, the recoverable amount of assets is higher than it carrying value and hence no impairment of assets needs to be recorded in the financial statements.
- In reference to **Note no. 19** the company has converted the financial statements of Depot Pharmacy Yego Ltd into INR as per the accounting standard 11 "The Effects of Changes in Foreign Exchange Rates.
- In reference to **Note no. 20** the company has prepared consolidated financial statements considering the results of its subsidiary companies as mentioned below: -

Name of subsidiaries	**Country**
Depot Pharmacy Yego Ltd. (Unaudited)	Rwanda, East Africa
Grande Etoile Pharmaceuticals Limited (Unaudited)	India

Our conclusion is not modified in respect of this matter.

For N C RAJ & ASSOCIATES
Chartered Accountants
(FRN: 002249N)



SANJAY GARG
Partner
Mem. No. 088636
Date: November 14th 2025
Place: New Delhi
UDIN: 25088636BMMJGY1070

MEDICAMEN ORGANICS LIMITED

Registered Address: 10, Community Centre No 2,
Ashok Vihar Phase II New Delhi - 110052
CIN : L74899DL1995PLC066416

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS AS AT SEPTEMBER 30TH, 2025

(Rs. in Lakhs)

	PARTICULARS	Figures as at the end of	
		As At 30.09.2025	As At 31.03.2025
		Unaudited	Audited
I.	**EQUITY AND LIABILITIES**		
1	**Shareholders' funds**		
	(a) Share Capital	1170.00	1170.00
	(b) Minority Interest	40.05	35.14
	(c) Reserves and Surplus	1966.77	1767.92
	(d) Money received against Share Warrants	125.00	75.00
		3301.81	**3048.07**
2	**Share Application Money Pending Allotement**		
3	**Non- current liabilities**		
	(a) Long-term borrowings	36.68	15.75
	(b) Deferred Tax liabilities	118.01	115.99
	(c) Long-term Provisions	26.96	25.34
		181.65	**157.08**
4	**Current Liabilities**		
	(a) Short term borrowings	1530.20	1219.56
	(b) Trade payables		
	- Outstanding dues of Micro and Small Enterprises	101.59	108.75
	- Outstanding dues to others	617.56	1061.56
	(c) Other current liabilities	161.12	176.43
	(d) Short term provisions	221.53	149.29
		2632.00	**2715.59**
	TOTAL	**6115.46**	**5920.74**
II	**ASSETS**		
1.	**Non-current assets**		
	(a) Property, Plant & Equipment		
	(i) Property, Plant & Equipment	1267.55	1011.54
	(ii) Intangible assets	11.31	1.43
	(iii) Capital work-in-progress	35.93	221.59
	(b) Non-Current Investment	-	-
	(b) Long-term Loans & Advances	-	-
	(c) Other Non-Current Assets	136.12	142.96
		1450.91	**1377.53**
2.	**Current assets**		
	(a) Inventories	820.01	748.94
	(b) Trade receivables	2808.04	2585.22
	(c) Cash and cash equivalents	290.51	413.03
	(d) Short-term loans and advances	746.01	796.03
	(e) Other current assets	-	-
		4664.55	**4543.22**
	TOTAL	**6115.46**	**5920.74**

For MEDICAMEN ORGANICS LTD.

Director

B.K. Gupta
(Chairman ~~cum Managing~~ Director)
DIN:00032772

Place : New Delhi
Date: 14th November 2025

MEDICAMEN ORGANICS LIMITED

Registered Address: 10, Community Centre No 2,
Ashok Vihar Phase II New Delhi - 110052
CIN : L74899DL1995PLC066416

STATEMENT OF UNAUDITED CONSOLIDATED PROFIT AND LOSS FOR THE HALF YEAR ENDED 30.09.2025

(Rs. in Lakhs)

	PARTICULARS	Note No.	For the Half Year ended			For the year ended March 31, 2025
			From 01-04-2025 to 30-09-2025	From 01-10-2024 to 31-03-2025	From 01-04-2024 to 30-09-2024	
			Unaudited	Audited	Unaudited	Audited
I	Revenue from operations:	21	1785.23	2157.72	1661.04	3818.77
II	Other Income	22	5.79	5.21	4.29	9.50
III	**Total Revenue (I + II)**		**1791.02**	**2162.94**	**1665.34**	**3828.27**
IV	**Expenses**					
	Cost of Materials Consumed	23	1067.00	1248.88	975.67	2224.54
	Direct Expenses	24	157.85	179.43	153.18	332.61
	Changes in inventories of finished goods, work in progress and Stock-in-trade	25	-112.90	-95.19	14.40	-80.79
	Employee benefits expense	26	189.77	191.83	174.62	366.46
	Finance Costs	27	33.37	29.19	22.17	51.36
	Depreciation and amortization expense	12	41.25	37.28	36.41	73.68
	Other expense	28	140.79	247.35	70.03	317.38
	Total Expense		**1517.13**	**1838.76**	**1446.48**	**3285.24**
V	**Profit before exceptional and extraordinary items and tax (III-IV)**		273.89	324.18	218.85	543.03
VI	**Exceptional Items**		-	-	-	-
VII.	**Profit before extraordinary items and tax (V-VI)**		273.89	324.18	218.85	543.03
VIII	**Prior Period Item/Extraordinary items(Loss**		-	-	-	0.00
IX	**Profit before tax (VII-VIII)**		**273.89**	**324.18**	**218.85**	**543.03**
X	**Tax expense:**					
	(1) Current tax		68.07	79.43	61.43	140.87
	(2) Deferred tax		2.02	-8.90	6.35	-2.55
XI	**Profit/(Loss) for the period from continuing operations (IX - X)**		203.80	253.64	151.07	404.71
XII	**Profit/(Loss) for the period**		**203.80**	**253.64**	**151.07**	**404.71**
XV	**Earnings per equity share:**					
	(1) Basic		**1.74**	**2.19**	**1.48**	**3.67**
	(2) Diluted		**1.71**	**2.18**	**1.48**	**3.66**

For MEDICAMEN ORGANICS LTD.

Director

B.K. Gupta
(Director)
DIN:00032772

Place : New Delhi
Date: 14th November 2025

MEDICAMEN ORGANICS LIMITED

Registered Address: 10, Community Centre No 2,
Ashok Vihar Phase II New Delhi - 110052
CIN : L74899DL1995PLC066416

UNAUDITED CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2025

(Rs. in Lakhs)

Particulars	Figures as at the end of	
	As At 30.09.2025	As At 31.03.2025
	Unaudited	Audited
	-	
Cash flow from operating activities		
Net profit before taxation, and extraordinary item	273.84	543.03
Non-cash adjustment to reconcile profit before tax to net cash flows		
Provision for Taxation	-	-
Depreciation/amortization on continuing operation	14.60	59.73
Interest expense	33.37	51.36
Interest income	-1.56	-9.48
Adjustment for Deffered Tax	-	-
Operating profit before working capital changes	**320.25**	**644.64**
Movements in working capital :		
Increase/(decrease) in trade payables	-451.16	462.34
Increase / (decrease) in long-term provisions	1.62	3.87
Increase / (decrease) in short-term provisions	4.17	-90.08
Increase/(decrease) in other current liabilities	-15.32	70.50
Decrease/ (increase) in long term loans and advances	0.00	32.50
Decrease/ (increase) in trade receivables	-222.82	-915.21
Decrease/ (increase) in inventories	-71.07	-134.67
Decrease / (increase) in other non-current Assets	6.85	-112.24
Decrease / (increase) in short-term loans and advances	50.03	-406.53
Decrease/(increase) in other current assets	-	-
Direct taxes paid (net of refunds)	0.00	-9.44
Net cash flow from/ (used in) operating activities (A)	**-377.46**	**-454.31**
Cash flows from investing activities		
Purchase of fixed assets, including intangible assets and CWIP	-94.83	-244.73
Investing to make Subsidiary and Associate concern	-	-
Interest received	1.56	9.48
Net cash flow from/(used in) investing activities (B)	**-93.27**	**-235.25**
Cash flows from financing activities		
Proceeds from issuance of share capital	-	310.00
Share Warrants A/c	50.00	75.00
Proceeds from Securities Premium	-	744.00
Repayment of long-term borrowings	20.93	-0.39
Proceeds from short-term borrowings	310.64	-29.95
Interest paid	-33.37	-51.36
Net cash flow from/(used in) in financing activities (C)	**348.21**	**1047.30**
Net increase/(decrease) in cash and cash equivalents (A + B + C)	**-122.53**	**357.73**
Cash and cash equivalents at the beginning of the year (D)	413.03	55.30
Cash and cash equivalents at the end of the year (E)	290.51	413.03
Difference in above D and E	**-122.53**	**357.73**

For MEDICAMEN ORGANICS LTD.

B.K. Gupta
(Managing Director)
DIN:00032772

Director

Place : New Delhi
Date: 14th November 2025

MEDICAMEN ORGANICS LIMITED

Registered Address: 10, Community Centre No 2,
Ashok Vihar Phase II New Delhi - 110052, India
CIN : L74899DL1995PLC066416

Notes to Accounts

1 The consolidated financial results are prepared in accordance with the Accounting Standards Prescribed urder Section 133 of the Companies Act,2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable.

2 The Statutory Auditors of the Company have reviewed of the above results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

3 There were no investor complaints known to the Company outstanding at the beginning and at the end of the half year ended on September 30th, 2025.

4 The results of the Company are also available for investors at www.medicamenorganics.com and www.nseindia.com

5 The above consolidated audited financial results for the Half year ended September 30th, 2025 have been prepared by the Company were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on November 14th, 2025, Above results has been reviewed by the statutory auditors of the company.

6 These financial results have been prepared in accordance with the recognition and measurement principles of Accounting Standards ("AS") prescribed section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and the other accounting principles generally accepted in India.

7 The company has received intimation from suppliers regarding their status under Micro, Small and Medium Enterprises Development Act 2006 and disclosures relating to the amount unpaid as at year end, as required under the said Act, have been provided. The Company has provided the interest on outstanding from supplier under Micro, Small and Medium Enterprises as on 30-09-2025.

8 The Earning Per Share (EPS) has been computed in accordance with the Accounting Standard on Earnings Per Share (AS 20). EPS for the half year ended September 30th, 2025, March 31st, 2025, and September 30th 2024 are not annuualised. The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earnings per share in accordance with the Accounting Standard 20.

9 The comparative results for the half-year ended September 30th, 2025 have been reviewed by the statutory auditors of the Company.

10 The figures for the half-year ended March 31st, 2025 are balancing figures between audited figures in respect of the full financial year ended March 31st, 2025 and the unaudited half-year ended September 30th 2024.

11 **CONTINGENT LIABILITIES AND PENDING LITIGATIONS**

a) **Contingent Liabilities** **(In Lakhs)**

Particulars	Next date of Hearing	As at 30-09-2025	As at 31-03-2025
a. Case against the company filed by Prakash Parcel Services Ltd.	10-12-2025	2.34	2.34
b. Margin money (FDR) for Bank Guarantee on behalf of third party		6.42	6.42

For MEDICAMEN ORGANICS LTD.

Director

b)

Name of the statute	Nature of the dues	Amount (Rs. in lakhs)	Financial Year	Description	Forum where dispute is pending
Income Tax Department	Income tax	13.27	AY 2017-18	Assessment year	Commissioner of income tax (Appeal)
GST	Difference in output tax liability & ITC claimed	5.87	2020-21	Reply is to be filed	Deputy Commissioner (Assessment)-2 Haridwar
GST	Difference in output tax liability & ITC claimed	89.73	2018-19	Appeal filed	Appeal filed before the Joint Commissioner (Appeals) Dehra Dun
GST	Difference in output tax liability & ITC claimed	74.51	2019-20	Appeal filed	Appeal to be filed before the Joint Comm. (Appeals) Dehra Dun
GST	Difference in output tax liability & ITC claimed	17.74	2022-23	Reply is to be filed	Deputy Commissioner (Assessment)-2 Haridwar

c) **Detail of Pending Litigation**

Name of the Party	Nature of the dues	Amount (Rs. in lakhs)	Next date of Hearing	Description	Forum where dispute is pending
Europa Biocare P Ltd	Civil Case	7.23	12-11-2025	The company has filed recovery suit (civil case) against the defaulter party	Rohini (Court)
M/S Wafture Healthcare P Ltd	Civil Case	5.7	24-12-2025	The company has filed recovery suit (civil case) against the defaulter party	Rohini (Court)
Paseca Health Care	Civil Case	5.53	05-12-2025	The company has filed recovery suit (civil case) against the defaulter party	Rohini (Court)
Ujjwal Overseas	Civil Case	17.17	05-12-2025	The company has filed recovery suit (civil case) against the defaulter party	Rohini (Court)
Mexlife Care LLP	Civil Case	18.22	23-02-2026	The company has filed recovery suit (civil case) against the defaulter party	Rohini (Court)
The Managing Director KSMSCL(Karnataka State)	Civil Case	148.22	12-11-2025	The company has filed recovery suit (civil case) against the defaulter party	Rohini (Court)

For MEDICAMEN ORGANICS LTD.

Director

Annexure A

12 During the period ended September 30th, 2025, the Company came up with the public issue of 31,00,000 equity shares of Face value of ₹ 10/- each ("equity shares") with the price band of ₹ 32 to 34 through Book Building Method, IPO was open for subscription from Friday, June 21, 2024 to Tuesday, June 25, 2024. The Company has allotted 31,00,000 equity shares of Face value of 10/- each ("equity shares") for cash at a price of ₹ 34/- per equity share (including a share premium of ₹ 24/- per equity share) aggregating to ₹ 1054.00 Lakhs on Wednesday, June 26, 2024. The equity shares of the Company got listed with Emerge platform of National Stock Exchange of India Limited on June 28, 2024. The issue was made in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.

Rs. In Lakhs

Object of the Issue as per Prospectus	Utilisation Planned as per prospectus	Total Utilisation up to September 30th, 2025	Amount Pending for Utilisation
Funding of expenses proposed to be incurred towards Product registration in the international markets	300	137.56	162.44
Plant updation and increase in production capacity	225	225	-
Funding working capital requirements of our Company	400	400	-
General corporate purposes	39	39	-
Issue Related Expenses	90	90	-
TOTAL	**1054**	**891.55815**	**162.44**

Note on Capitalisation of Product Registration Expenses (Object of the Issue)

As stated in the **Objects of the Issue** in the Company's Prospectus, one of the purposes of the public issue is to incur expenditure towards **Product Registration and Intellectual Property (IP) Development**.

Accordingly, the Company has incurred various expenses towards the registration and development of new products, and as per Prospectus of the company, Registration involves the preparation and submission of data dossiers which require detailed product specifications, understanding of the market dynamics and accurate compilation of required documents. Detailed study on the effect and the efficacy of the product is required to be conducted and details of the results of these studies are submitted as part of the registration process.

Expenditure directly attributable to such activities has been treated as part of **"Intellectual Property (IP) Work-in-Progress"**, in accordance with the recognition criteria laid down in **AS 26– Intangible Assets**.

The following costs have been capitalised under *IP Work-in-Progress* :

Regulatory and product registration fees;

Registration involves the preparation and submission of data dossiers which require detailed product specifications, understanding of the market dynamics and accurate compilation of required documents. Detailed study on the effect and the efficacy of the product is required to be conducted and details of the results of these studies are submitted as part of the registration process.

Upon completion of the registration process and readiness for commercial production, the cumulative expenditure will be **transferred from "IP Work-in-Progress" to "Intangible Assets – Product Registration / Intellectual Property"**, and **amortised over its estimated useful life**.

* The unutilsed proceeds are in company's account.

For MEDICAMEN ORGANICS LTD.

Director

13 During the financial year ended March 31, 2025, the Company came up with the preferential issue of 4,65,910 warrants convertible into equivalent number of fully paid-up equity shares of face value of ₹ 10/- (Rupee Ten Only) each ("Equity Shares") at the option of Allottees, in one or more tranches, within 18 (eighteen) months from the date of allotment at issue price of ₹ 64.39/-.
The issue was made in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.

In Lakhs

Object as disclosed in the offer document	Nature	Amount disclose in the Offer Document/ Postal Ballot Notice dated January 08, 2025 (Rs. In Lakhs)	Actual Utilised Amount (as on September 30, 2025)	Unutilised Amount (As on September 30, 2025)	Remarks, If any
(a) working capital requirements;	4,65,910 Share Warrants convertible into Equity Shares	299.99	123.25	-	As on September 30, 2025, funds received against the warrants subscription money on 4,65,910 warrants amounted to ₹2,99,99,945, constituting 41.67% of the total funds raised. Out of the received funds, the Company has spent ₹1,25,00,000 towards the objects disclosed in the offer document/Postal Ballot Notice.
(b) general corporate purpose.			1.75	-	
Total	**Total**	**299.99**	**125.00**	-	

14 Balances of some debtors and creditors are subject to their confirmations.

15 As per the assessment of the management, the recoverable amount of assets is higher than it carrying value and hence no impairment of assets needs to be recorded in the financial statements.

16 Previous year/period's figures have been regrouped/reclassified wherever necessary to correspond with the current period's classification for comparison.

17 As the Company's business activity falls within a single primary business segment i.e. the disclosure requirements as per AS 17 "Segment Reporting" are not applicable.

18 The books of accounts of the foreign subsidiary (Depot Pharmacy Yego Ltd) is not required to be audited, as no audit required in Rwanda.

19 The Medicamen Organics Limited has converted the financial of Depot Pharmacy Yego Ltd as per the Accounting standard 11 "The Effects of Changes in Foreign Exchange Rates".

20 Accounting Standard 21"Consolidated Financial Statements" is applied in the preparation and presentation of consolidated financial statements for a group of Subsidiary enterprises under the control of a parent.

The financial results includes the results of the following entities:-

Name of the Subsidiary	Country	Remarks
a) Grande Etoile Pharmaceuticals Limited	India	Unaudited
b) Depot Pharmacy Yego Ltd	Rwanda, East Africa	Unaudited

For & on behalf of Medicamen Organics Limited

For MEDICAMEN ORGANICS LTD.

Director

Bal Kishan Gupta
(Chairman cum Managing Director)
DIN:00032772

Place : New Delhi
Date: 14th November 2025

N C RAJ & ASSOCIATES
Chartered Accountants
10, Community Centre No.2,
Ashok Vihar Phase-II,
Delhi – 110 052
Phone: +911149057181
Website: www.ncraj.com
Email: info@ncraj.com
Peer Review No.: 014034

Annexure II

Date: November 14th, 2025

To,
National Stock Exchange Limited
Exchange Plaza, C-1 Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai-400051.

NSE Symbol: MEDIORG

Subject: Certificate on Utilization of Funds Raised through Issue Proceeds.


We N C Raj & Associates, FRN: 002249N, Statutory Auditor of M/s MEDICAMEN ORGANICS LIMITED, hereby certify that the Company raised funds through two sources, and the details of the original allocation and actual utilization of funds are as follows:

1. **Initial Public Offering (IPO):** The original allocation of funds as disclosed in the prospectus and the actual utilization of funds towards the objects of the issue for the half year ended September 30, 2025, are detailed in **Annexure A**.

2. **Preferential Issue against Convertible Share Warrant:** The original allocation of funds in relation to the proceeds and the actual utilization of funds towards the objects of the issue for the half year ended September 30, 2025, are detailed in **Annexure B**.

This certificate is issued at the request of the Company for specific purposes only and is based on our examination of the information and documents provided to us for verification.

For N C Raj & Associates
Chartered Accountants
(FRN: 002249N)



SANJAY GARG
Partner
Mem. No. 088636
Date: 14th November, 2025
Place: New Delhi
UDIN: 25088636BMMJGZ6608

Encl: - Annexure-A and Annexure- B

Annexure A in accordance with NSE Circular No. NSF/CMl/2024/23 dated September 05, 2024

Objects for which funds have been raised and where there has been utilised in the following table

UTILIZATION OF FUND

(₹ in Lakhs)

Sl. No.	**Object as Disclosed in the Offer Document**	**Amount disclosed in the Offer Document**	**Actual Utilised mount (As on 30th September, 2025)**	**Unutilised Amount (As on 30th September 2025)**	**Remark**
1	Funding of expenses proposed to be incurred towards Product registration in the international markets	300.00	137.56*	162.44	-
2	Plant updation and increase in production capacity	225.00	225.00	-	-
3	Funding working capital requirements of our Company	400.00	400.00	-	-
4	General corporate purpose	39.00	39.00	-	-
5	Issue Related Expenses	90.00	90.00	-	-
	Total	**1054.00**	**891.56**	**162.44**	-

***** This amount includes the advances given to consultants facilitating the product registration in the international markets.

Annexure B in accordance with NSE Circular No. NSF/CMl/2024/23 dated September 05, 2024

Objects for which funds have been raised and where there has been utilized in the following table:-

UTILIZATION OF FUND

(₹ in Lakhs)

Sl. No.	**Object as Disclosed in the Offer Document**	**Amount disclosed in the Offer Document Postal Ballot Notice dated 8th January 2025**	**Actual amount received (As on 30th September, 2025)**	**Actual Utilised amount (As on 30th September, 25)**	**Unutilised Amount (As on 30th September 25)**	**Remark**
1	Funding working capital requirements of our Company	299.99	125.00	125.00	-	As on 30th September, 2025 fund received against the warrants subscription amount money on 465910 warrants against Rs.64.39 per warrant Constituting 25% of the total fund raised. Out of the received funds the Company has spent Rs. 125,00,000 towards the object disclosed in the offer document.
2	General corporate purposes					
	Total	**299.99**	**125.00**	**125.00**	**-**	

Note:

1. During the year ended 31st March, 2025, the Company came up with the preferential issue of 4,65,910 warrants of face value of Re. 10/- (Rupee Ten Only) each ("Equity Shares") at the option of Allottee, in one or more tranches, within 18 (eighteen) months from the date of allotment at issue price of Rs 64.39/-. The issue was made in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 as amended.

2. Fund utilized as on September 30, 2025 is Rs. 125.00 (In Lakhs). The unutilized fund as on September 30, 2025 is "Nil".

MEDICAMEN Organics Limited
Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)
Tel: 011-27430249, 27138171
E-mail: info@mediorganics.in | CIN No: L74899DL1995PLC066416 | GSTIN:07AABCM4302P1ZF

Annexure III

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sr. no.	Particulars	Appointment of Internal Auditor of Mr. Shobhit Gupta , Practising Chartered Accountant
1.	Reason for change viz. appointment, ~~reappointment, resignation, removal, death or Otherwise~~.	Appointment of Internal Auditor
2.	Date of appointment / ~~reappointment/ cessation (as applicable)~~	Board meeting held on 14th November,2025 Appointed for 2025-26
3.	Term of Appointment /~~reappointment~~	1 year
4.	Brief profile (in case of appointment)	Mr. Shobhit Gupta, Member No. 502897, Practising Chartered Accountant ,proprietor of M/s Gupta Shobhit & Associates., Chartered Accountants (Firm Registration No. 041719N). He possesses extensive professional experience in the fields of internal audit, statutory audit, tax advisory, and financial reporting. He has been actively involved in conducting comprehensive internal audits for various corporate clients across manufacturing, trading, and service sectors. His expertise includes evaluating internal control systems, reviewing financial and operational processes, identifying risk areas, and suggesting corrective measures for strengthening governance and compliance frameworks. He is well-versed with Companies Act, 2013, Accounting Standards, Internal Financial Controls (IFC), and other regulatory requirements, ensuring thorough and reliable audit outcomes.
5.	Disclosure of relationships between directors (in case of appointment of a Director)	N.A.
6.	Information as required pursuant to BSE Circular ref. no. LIST/COMP/14/ 2018- 19 and NSE ref. no. NSE/CML/2018/24, dated June 20, 2018.	N.A.